The effect of different doses of estrogen to prevent adhesion recurrence after hysteroscopic lysis in Asherman's syndrome: A randomized clinical trial study

Document Type : Original Article

Authors

1 Professor, Department of obstetrics & Gynecology, Fellowship of Gynecology Laparascopy, Supporting of the Family and the Youth of Population Research Core, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Associate Professor, Department of obstetrics & Gynecology, Fellowship of Gynecology Laparascopy, Supporting of the Family and the Youth of Population Research Core, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Gynecologist, Department of obstetrics & Gynecology, Fellowship of Gynecology Laparascopy, Supporting of the Family and the Youth of Population Research Core, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

10.22038/ijogi.2024.74507.5851

Abstract

Introduction: Intrauterine adhesion is a condition that can lead to infertility, amenorrhea, repeated abortion in the patient, and the treatment of these patients is usually associated with many challenges. The present study was performed with aim to compare the effect of two different doses of estrogen to prevent the recurrence of adhesions after hysteroscopic lysis in Asherman's syndrome.
Methods: This randomized controlled clinical trial study was performed on 30 patients with moderate and severe Asherman's syndrome in Imam Reza Hospital of Mashhad, 2017-2021. Patients underwent hysteroscopy to remove adhesions. For all patients, an intrauterine balloon was placed after the operation and then they were treated with estrogen for 30 days and medroxyprogesterone 10 mg daily for the last 10 days. Patients were randomly assigned to two groups of estrogen 2.5 mg and 5 mg daily. After the end of the treatment period, with hysteroscopy again, the state of the uterine cavity was checked and the response to the treatment was compared in terms of the return of adhesions and its intensity in the two groups. Data were analyzed using SPSS software (version 26) and Shapiro-Wilk and Mann-Whitney U statistical tests. P<0.05 was considered statistically significant.
Results: The most common cause of Asherman in the 2.5 mg group was curettage (60%) and in the 5 mg group, other surgeries (60%). The two groups had no statistically significant difference in terms of confounding variables including age, cause of Asherman's disease and severity of adhesions (p=0.714). In examining the response to treatment, there was no statistically significant difference between the two groups in terms of adhesion severity in repeated hysteroscopy (p=0.858) and response to treatment (p=0.714).
Conclusion: For the prevention of recurrence of intrauterine adhesions (Asherman's syndrome) after hysteroscopic lysis of adhesions, the dose of 2.5 mg of Conjugated estrogen was as effective as the dose of 5 mg of estrogen.

Keywords

Main Subjects

References

  1. Touboul C, Fernandez H, Deffieux X, Berry R, Frydman R, Gervaise A. Uterine synechiae after bipolar hysteroscopic resection of submucosal myomas in patients with infertility. Fertility and Sterility 2009; 92(5):1690-3.
  2. Naghshineh E, Rouholamin S, Derakhshandeh Z. Hormone therapy with or without platelet-rich plasma (PRP) for treatment Asherman syndrome; A randomized clinical trial. Advanced Biomedical Research 2023; 12(1):17.
  3. Klein SM, García CR. Asherman's syndrome: a critique and current review. Fertility and sterility 1973; 24(9):722-35.
  4. Schenker JG. Etiology of and therapeutic approach to synechia uteri. European Journal of Obstetrics & Gynecology and Reproductive Biology 1996; 65(1):109-13.
  5. Roge P, D'Ercole C, Cravello L, Boubli L, Blanc B. Hysteroscopic management of uterine synechiae: a series of 102 observations. European journal of obstetrics & gynecology and reproductive biology 1996; 65(2):189-93.
  6. Fuchs N, Smorgick N, Ami IB, Vaknin Z, Tovbin Y, Halperin R, et al. Intercoat (Oxiplex/AP gel) for preventing intrauterine adhesions after operative hysteroscopy for suspected retained products of conception: double-blind, prospective, randomized pilot study. Journal of Minimally Invasive Gynecology 2014; 21(1):126-30.
  7. Taskin O, Sadik S, Onoglu A, Gokdeniz R, Erturan E, Burak F, et al. Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery. The Journal of the American Association of Gynecologic Laparoscopists 2000; 7(3):351-4.
  8. Kelley AS, Giuliani E, Schon SB. Secondary Prevention of Intrauterine Adhesions Following Hysteroscopic Surgery in Women With Asherman Syndrome: Is Something Better Than Nothing?. Clinical Obstetrics and Gynecology 2020; 63(2):320-6.
  9. Orhue AA, Aziken ME, Igbefoh JO. A comparison of two adjunctive treatments for intrauterine adhesions following lysis. International Journal of Gynecology & Obstetrics 2003; 82(1):49-56.
  10. Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome—one century later. Fertility and sterility 2008; 89(4):759-79.
  11. Adhesions AD. The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, Mullerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49(6):944.
  12. Taylor HS, Pal L, Sell E. Speroff's clinical gynecologic endocrinology and infertility. Lippincott Williams & Wilkins; 2019.
  13. AAGL Elevating Gynecologic Surgery j. abbott@ unsw. edu. au. AAGL practice report: practice guidelines on intrauterine adhesions developed in collaboration with the European Society of Gynaecological Endoscopy (ESGE). Gynecological Surgery 2017; 14(1):6.
  14. Farhi J, Bar-Hava I, Homburg R, Dicker D, Ben-Rafael Z. Induced regeneration of endometrium following curettage for abortion: a comparative study. Human Reproduction 1993; 8(7):1143-4.
  15. Myers EM, Hurst BS. Comprehensive management of severe Asherman syndrome and amenorrhea. Fertility and sterility 2012; 97(1):160-4.
  16. Robinson JK, Colimon LM, Isaacson KB. Postoperative adhesiolysis therapy for intrauterine adhesions (Asherman's syndrome). Fertility and sterility 2008; 90(2):409-14.
  17. Lin XN, Zhou F, Wei ML, Yang Y, Li Y, Li TC, et al. Randomized, controlled trial comparing the efficacy of intrauterine balloon and intrauterine contraceptive device in the prevention of adhesion reformation after hysteroscopic adhesiolysis. Fertility and sterility 2015; 104(1):235-40.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 27, Issue 2
April 2024
Pages 1-9

Files

Share

How to cite

Statistics